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Background: Gastric cancer (GC) is a major leading cause of cancer mortality worldwide.
Polyadenylate (poly(A))-binding protein (PABP)-interacting protein 1 (Paip1) is a key
regulator in the initiation of translation; however, its role in GC remains to be investigated.
Purpose: The purpose of this study is to determine Paip1 expression levels and investigate
its underlying molecular mechanism in GC.
Patients and methods: In the present study, a total of 90 GC samples and 90 adjacent
noncancerous tissues were used to examine the expression of Paip1. In order to gain a deep insight
into the molecular mechanism of Paip1 in GC, the Paip1 siRNA sequences were transfected into
GC cell lines (MGC-803 and SGC-7901), respectively. Meanwhile, Paip1 plasmid was used to
mediate overexpression of Paip1. Cell proliferation were examined via colony formation assay,
EdU assay and flow cytometry assay. Cell metastasis were discovered via wound healing assay and
Transwell assays. In addition, key EMT makers were detected by Western blotting assay.
Results: In this study, Paip1 expression was observed to be upregulated in GC and was
associated with shorter overall survival. Knockdown of Paip1 inhibited cell proliferation,
migration and caused cell cycle arrest in GC cells, whereas its overexpression reversed these
effects. Another mechanistic study showed that Paip1 overexpression promoted EMT pro-
gression and regulated its targets expression.
Conclusion: High expression of Paip1 plays a significant role in the progression of GC and
may be a potential biomarker of poor prognosis as well as a therapeutic target.
Keywords: Paip1, metastasis, proliferation, gastric cancer, prognostic marker
Introduction
GC is one of the leading causes of cancer-related deaths worldwide and occurs with
the highest frequency in China.1,2 According to Chinese statistics from 2015, 679
100 new cases of GC were diagnosed, and 498 000 patients died in 2015. Residents
of rural areas were reported to have significantly higher incidence and mortality
rates than urban residents.3 These studies show that incidence rates of GC depend
on geography. Due to the limited clinical approaches for the early diagnosis and
treatment of GC, the prognosis for GC patients is far from optimistic. Therefore, a
comprehensive understanding of the etiology and mechanisms of GC development
could benefit the identification of novel targets associated with GC.
The mammalian PABP-binding protein is polyadenylate-binding protein-inter-
acting protein 1 (Paip1), which can stimulate the initiation of translation by binding
PABP.4,5 Protein synthesis regulation at translation initiation is a crucial mechanism
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for regulating cell proliferation and differentiation.6,7
Recently, many studies have reported that imbalances in
this process may contribute to cell immortalization and
oncogenic transformation.8,9 Based on these studies,
Paip1 might be involved in cancer development and pro-
gression. Previous research has demonstrated that Paip1 is
overexpressed in invasive cervical cancer and amyotrophic
lateral sclerosis and participates in the malignant progres-
sion of cervical epithelial cells.10,11 However, the mechan-
isms underlying these tumor-promoting effects of Paip1
are still not well understood.
In the present study, we explored the role of Paip1 in
GC. The results showed that knockdown of Paip1 inhib-
ited the proliferation and metastasis of GC cells. These
results suggest that Paip1 is a novel oncogene in GC that
could be used as an additional diagnostic target and a
potential therapeutic target for GC patients.
Materials and methods
Ethics statement
This study complied with the principles of the Declaration
of Helsinki and was approved by the human ethics and
research ethics committees of Yanbian University Medical
College in China. All patients whose tissues used in this
research were provided written informed consent. Their
resected specimens were stored by our hospital and will
potentially be used for scientific research. Their privacy
will be maintained. The Follow-up survival data were
collected retrospectively through medical-record analyses.
Tissues and specimens
A total of 90 cases of surgically resected GC and 90
cases of peritumoral gastric tissues were collected from
the files of Yanbian University Cancer Research Center.
All patients are Han nationality, from Jilin Province,
China. All patients did not receive chemotherapy. All
cases were reviewed by two pathologists, and the histo-
logical diagnoses were confirmed without discrepancy.
All samples were routinely fixed in 10% buffered for-
malin and embedded in paraffin blocks. The pathologi-
cal parameters, including age, gender, tumor invasion,
histological grade, lymph node metastasis, lymphatic
invasion, clinical stage and survival data, were
reviewed. Overall survival (OS) time was defined as
the time from surgery to cancer-related death. The
pathological parameters considered in this study are
summarized in Table 1.
Immunohistochemical (IHC) analysis
Immunohistochemical (IHC) analysis was performed
using a Dako LSAB kit (Dako A/S, Glostrup,
Denmark). Tissue sections were deparaffinized, hydrated
and incubated with 3% H2O2 in methanol. Next, the
antigen was restored and then incubated with 1% bovine
serum albumin. The slides were incubated overnight at
4 °C with a primary antibody. Then, the cells were
incubated with a secondary antibody for 30 min, followed
by diaminobenzidine (DAB), and counterstained with
Mayer’s hematoxylin. Using a rabbit IgG isotope as a
negative control, positive tissue sections were processed,
and the primary antibody was omitted as an additional
negative control.
Two pathologists analyzed the samples without
knowledge of the clinical results of all tissue samples.
If there was a difference between the two analyses, the
two pathologists reassessed the samples on a double-
headed microscope to determine the final score. In
short, the staining intensity was scored as 0 (negative),
1 (weak), 2 (intermediate) and 3 (strong). The staining
proportion was scored as 0 (<10%), 1 (11–25%), 2
(26–50%), 3 (51–75%) and 4 (76–100%). The intensity
and proportion scores were used to calculate the final
immunoreactive score. Tissue sections scored as ≥4
were considered a strong positive (high expression
level) of Paip1 protein. The immunoreactive scores
were grouped as strong (≥4) and weak (<4) for survival
analysis.
Table 1 Paip1 protein expression in gastric cancer and adjacent-nontumor tissues
Diagnosis No. of cases Paip1 expression Positive rate (%) Strongly positive rate (%)
- + ++ +++
Gastric cancers 90 13 40 28 9 85.5** 41.1**
Normal tissues 90 57 27 6 0 36.6 7.0
Note: **Mean p<0.01. Positive rate percentage of positive cases with “+”, “++”, and “+++” staining score; Strongly positive rate percentage of positive cases with “++” and
“+++” staining score.
Wang et al Dovepress
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UALCAN database
UALCAN is a user-friendly and interactive web resource
for analyzing cancer transcriptome data. We analyzed the
mRNA expression of Paip1 using the UALCAN database,
which included 415 GC samples and 34 normal gastric
tissue samples.12
Cell culture
Four human cancer cell lines (MGC-803, BGC-823, SGC-
7901, and AGS) and a normal gastric epithelial cell line
(GES-1) were obtained from the Chinese Academy of
Medical Sciences Cell Bank and stored at Yanbian
University Cancer Research Center. The cells were cul-
tured in RPMI 1640 medium (Gibco, Gaithersburg, MD,
USA) supplemented with 10% fetal bovine serum and
100 U/ml penicillin/streptomycin and then placed in a
humidified 5% CO2 incubator at 37 °C.
Paip1 knockdown and overexpression
SiRNAwas transfected with Lipofectamine 3000 (Invitrogen,
CA, USA) according to the manufacturer’s instructions. The
siRNA1 and siRNA2 sequences were 5ʹ-
GGATTATCCTACTCTATCA-3ʹ and 5ʹ-GTGGCAACT
TCCGCCAATT-3ʹ, respectively. Nontargeting siRNA was
used as a negative control (siCON). All of the primer sequences
were synthesized by RiboBio (Guangzhou, China). Protein
expression levels were analyzed after 48 h of transfection.
Human Paip1 cDNA was purchased form (Genechem)
and cloned into the GV144 plasmid. The Paip1 plasmid
and corresponding empty vector were transfected into GC
cell using Lipofectamine 3000 reagent (Invitrogen)
according to the manufacturer’s protocol.
Western blotting
Cells were washed twice with ice-cold PBS and then lysed in
RIPA lysis buffer (CWBIO). The protein concentration of the
lysates was determined with the Bradford reagent (Aid Lab).
Equal amounts of proteins were separated on SDS polyacry-
lamide gels and transferred to polyvinylidene fluoride
(PVDF) membranes. The membranes were blocked with
5% fat-free milk and immunoblotted overnight at 4 °C with
primary antibodies followed by the corresponding secondary
antibodies for 1 h. β-actin was used as the loading control.
The membranes were detected using enhanced chemilumi-
nescent (ECL) Prime Western blotting detection reagent
(Amersham Biosciences, Uppsala, Sweden). Images were
acquired with a Champchemi Professional image analysis
system (Sagecreation, Beijing, China) and quantified using
LANE 1D software (Sagecreation).
Immunofluorescence (IF) staining analysis
IF staining was used to analyze the subcellular localization of
the Paip1 protein in MGC-803 and SGC-7901 cells. The cells
were grown on coverslips to 65–75% confluence, fixed with
3.65% paraformaldehyde for 5 min and penetrated with 0.5%
TritonX-100 for 12 min. After blocking with 3% bovine serum
albumin fraction V (A8020, Solarbio, Beijing, China) for 1.5 h,
the slides were quickly washed with phosphate-buffered saline
(PBS) three times. Then, the cells were incubated overnight at
4 °C with a primary antibody followed by incubation with
Alexa Fluor 488 goat anti-rabbit IgG (H + C) (A11008,
1:1000 dilution, Invitrogen, USA) for 1 h. After washing with
PBS, the cells were counterstained with diamidino phenylin-
dole (DAPI) (C1006, Beyotime, Shanghai, China) and fixed on
a slide. Finally, the IF signalswere observed and imaged using a
Leica SP5II CLSM microscope (Heidelberg, Germany) with
filters for the corresponding fluorescent stains.
Colony formation assay
Cells were seeded at a density of 5×103cells in six-well
plates and incubated at 37 °C for approximately
2–3 weeks. Even if not observed under the microscope,
the culture was terminated when the clones were clearly
visible. The number of colonies containing more than 50
cells was counted using crystal violet staining and an
Olympus phase contrast microscope.
Flow cytometry analysis of the cell cycle
For cell cycle analysis, MGC-803 and SGC-7901 cells
were transfected with Paip1 or siCON for 48 h seeded in
6-well plates and cultivated for 24 h. Then, the cells were
collected and fixed in 75% ethanol at 4 °C for 24–48 h and
stained with 300 μl propidium iodide (PI) (BD
Biosciences, Bedford, MA, USA). Finally, the cell cycle
distribution was analyzed by an Accuri C6 flow cytometer
(Accuri, Ann Arbor, MI), and the data were analyzed with
ModFit (Verity Software House, Topsham, ME).
5-ethynyl-2ʹ-deoxyuridine (EdU)
incorporation assay
MGC-803 and SGC-7901 cells transfected with Paip1 or
siCON were plated in 96-well plates at a density of 5×104
cells/well and then treated with 50 mM EdU for an addi-
tional 2 h at room temperature. Then, the cells were fixed
Dovepress Wang et al
OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com
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with 4% paraformaldehyde for 15 min. After washing with
3% BSA (bovine serum albumin), the cells were permea-
bilized with 0.5% Triton X-100 for 20 min. After washing
with PBS, 500 ml Click-iT mix was added to each well,
and the cells were incubated for 30 min. Finally, the cells
were stained with 1 ml Hoechst 33342 for 15 min and
observed under a Leica SP5II CLSM microscope.
Wound healing assay
Cells were seeded in 6-well plates and allowed to grow
until 90% confluent. scratched with a 10-μl pipette tip and
washed twice with PBS to remove the nonadherent cells.
Then, the cells were incubated in growth media that
changes its distribution to reflect cell migration. Wound
closure was analyzed after 0, 12, 24 and 48 h (indicated by
cell migration to the scratched acellular area). All experi-
ments were performed in triplicate.
Transwell assays
Cell migration was determined using 24-well transwell
plates with 8-μM pore sizes. Cell invasion was analyzed
using the same transwell inserts coated with Matrigel.
Cells (5.0×104/500 μL serum-starved medium) were
added to the upper chambers, and complete medium was
added to the bottom wells. After incubating for 48 h at
37 °C, 4% paraformaldehyde was added to both chambers
for 1 min at room temperature. The upper faces of the
filters were then wiped with cotton swabs. Then, Giemsa
staining (Wako) was performed, and invading and migrat-
ing cells were counted using a microscope.
Statistical analysis
Statistical analyses were performed using SPSS/Win17.0
software (SPSS, Inc., Chicago, IL, USA) and GraphPad
Prism® version 7.00 (GraphPad Software, USA). The
results are presented as the mean ± SD. All observations
were confirmed by at least three independent experi-
ments. Survival curves were analyzed by the log-rank
Kaplan-Meier method followed by log-rank testing for
univariate analysis. Multivariate analyses were per-
formed using Cox’s proportional hazards regression
model. p<0.05 was considered statistically significant.
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Figure 1 Paip1 expression was upregulated in GC.
Notes: (A), a, Paip1 expression was downregulated in adjacent nontumor tissue. b, Paip1 was weakly positive in GC tissue. c, Paip1 was positively expressed in GC tissue.
d, Paip1 was strongly positive in GC tissue. Original magnification ×200. (B) The UALCAN dataset showed that the average Paip1 mRNA expression level was higher in GC
tissues than in normal gastric tissue. (C) Western blot analysis of Paip1 in a normal human gastric cell line (GES-1) and GC cell lines (AGS, SGC-7901, BGC-823 and MGC-
803). The expression levels were normalized to β-actin. (D) IF analysis showed that Paip1 (red) was strictly located in the cytoplasm of MGC-803 and SGC-7901 cells.
Original magnification was ×400; blue indicates DAPI staining; red indicates Paip1 staining. **p<0.01.
Abbreviations: GC, gastric cancer; DAPI, 4ʹ,6-diamidino-2-phenylindole.
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Colony formation and cell migration and invasion levels
were compared using Student’s t-test or Mann-Whitney
U test.
Results
Paip1 is frequently overexpressed in GC
To identify the expression status of Paip1, we first performed
IHC staining of GC tissues and adjacent normal gastric tissues.
The results showed that Paip1 expression was upregulated in
GC tissues compared to adjacent normal tissues (Figure 1A).
As shown in Table 1, the positive rate was 85.5% inGC tissues
(77/90), which was significantly greater than that in adjacent
normal gastric tissues (36.6%, 33/90; p<0.01). Similarly, the
strongly positive rate of Paip1 protein in GC tissues (41.1%,
37/90) was significantly greater than that in adjacent normal
gastric tissues (7%, 6/90; p<0.01) (Table 1). Additionally, we
evaluated the mRNA expression level of Paip1 in clinical
samples using microarray data obtained from the UALCAN
dataset, which indicated that the Paip1 expression level in GC
tissues was greater than that in adjacent normal tissues (Figure
1B). Then, we analyzed the expression levels of Paip1 in four
human GC cell lines (AGS, SGC-7901, BGC-823 and MGC-
803) and a normal gastric epithelial cell line (GES-1). The
results demonstrated that the expression levels of Paip1 were
significantly increased in human GC cell lines compared the
GES-1 gastric epithelial cells (Figure 1C). Moreover, IF ana-
lysis also confirmed that Paip1 was located in the cytoplasm of
GC cells (Figure 1D). These results provide support for the
overexpression of Paip1 in GC.
Paip1 overexpression is associated with
poor patient outcome in GC
According to the results of IHC, correlation analysis
showed that protein expression level of Paip1 was signifi-
cantly correlated with patient age, lymphatic invasion and
clinical stage. However, the expression level of Paip1 was
not related to gender, LN metastasis or histological stage
(Table 2 and Figure 2A–C). Univariate analysis demon-
strated that age, tumor invasion, lymphatic invasion, clin-
ical stage and Paip1 expression were associated with the
overall survival (OS) rate of GC patients (Table 3). In
addition, multivariate analysis using Cox’s proportional
hazards model for all significant variables examined in
the univariate analysis showed that age, tumor invasion
and Paip1 expression were independent prognostic factors
for GC patients (Table 3). Similar to univariate and multi-
variate analyses, patients whose tumors expressed a high
level (++/+++) of Paip1 had a significantly shorter overall
survival time than those whose tumors expressed a low
level (−/+) of Paip1 (p<0.001) (Figure 2D). For late-stage
(II–IV) GCs, OS rates were significantly higher in patients
with low Paip1 expression than in those with high expres-
sion (p<0.05) (Figure 2E). By combination analysis, we
found that the expression of Paip1 protein did not correlate
with the survival rate of patients with early stage GC
(p>0.05) (Figure 2F). Overall, these data suggest that
Paip1 might be a potential prognostic factor in GC.
Table 2 Correlation between Paip1 expression and clinicopatho-
logical parameters of gastric cancer patients
Clinical features No. of
Cases
Strongly
positive
cases (%)
χ2 p-value
Gender 2.303 0.129
Male 68 31 (45.6)
Female 22 6 (27.3)
Age 5.148 0.023*
<65 37 10 (27.0)
≥65 53 27 (50.9)
Histological grade 1.795 0.180
Grade-I, II 29 9 (31.0)
Grade-III 61 28 (45.9)
Tumor invasion 2.086 0.149
T1-T2 16 4 (25.0)
T3-T4 74 33 (44.6)
LN metastasis 2.171 0.141
Positive 37 12(86.5)
Negative 53 25(64.2)
Lymphatic
invasion
5.559 0.018*
Positive 66 32 (48.4)
Negative 24 5 (31.2)
P53 0.008 0.927
Positive 37 15 (40.5)
Negative 53 22 (41.5)
Clinical stage 8.284 0.004**
Stage I 30 6 (20.0)
Stage II, III, IV 60 31 (51.7)
Note: *Mean p<0.05. **Mean p<0.01. Age: p=0.023; Lymphatic invasion: p=0.018;
and Clinical stage: p=0.004.
Abbreviations: LN metastasis, Lymph node metastasis.
Dovepress Wang et al
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Figure 2 Survival rate of sub-groups in gastric cancer.
Notes: (A-C) The relationships between Paip1 expression and the clinicopathologically significant aspects of GC. (D) Kaplan-Meier analysis of Paip1 (−/+) (53 cases) and
Paip1 (++/+++) (37 cases) showed significant differences in GC. (E) Kaplan-Meier analysis of Paip1 (−/+) (28 cases) and Paip1 (++/+++) (6 cases) showed no significant in the
early-stage GC. (F) Kaplan–Meier analysis of Paip1 (−/+) (25 cases) and Paip1 (++/+++) (31 cases) showed significant differences in the late-stage GC.
Table 3 Univariate survival analyses (Cox regression model) of various factors in patients with gastric cancer
Factors B SE Wald HR 95%CI p-value
Lower Upper
Univariate
Gender 0.176 0.314 0.316 1.193 0.645 2.207 0.574
Age 0.628 0.278 5.096 1.874 1.086 3.233 0.024*
Tumor invasion 1.565 0.594 6.937 4.783 1.492 15.327 0.008**
Histological grade 0.451 0.287 2.462 1.569 0.894 2.755 0.117
LN metastasis 0.223 0.298 0.558 0.673 0.696 2.243 0.455
Lymphatic invasion 1.074 0.363 8.734 2.927 1.436 5.967 0.003**
Clinical stage 1.250 0.337 13.784 3.491 1.804 6.755 0.001**
P53 0.373 0.260 2.058 1.452 0.872 2.417 0.151
Paip1 0.804 0.261 9.492 2.235 1.340 3.729 0.002**
Multivariate
Clinical stage 0.875 0.521 2.822 2.399 0.864 6.661 0.093
Age 0.611 0.289 4.473 1.791 1.046 3.243 0.034*
Tumor invasion 1.185 0.604 3.849 3.270 1.001 10.681 0.050
Lymphatic invasion 0.077 0.565 0.019 1.080 0.357 3.268 0.891
Paip1 0.743 0.265 7.874 2.103 1.251 3.535 0.005**
Note: *Mean p<0.05. **Mean p<0.01.
Abbreviations: LN metastasis, lymph node metastasis; B, Coefficient; SE, standard error; Wald, Wald statistic; HR, hazard ratio; CI; confidence interval.
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Figure 3 Silencing Paip1 inhibited cell proliferation.
Notes: (A) Western blot analysis of Paip1 expression in MGC803 and SGC-7901 cells. (B) Representative images of the colony formation assay in MGC803 and SGC-7901
cells treated with siCON and siRNA1. (C) The proliferative ability of MGC-803 and SGC-7901 cells transfected with siCON and siRNA1 was analyzed by Edu staining. Each
column shows the mean of three independent experiments. Each bar represents the mean ± SD. **p<0.01.
Abbreviations: siCON, non-targeting siRNA; siRNA, small interfering RNA.
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Silencing of Paip1 expression suppressed cell
proliferation and induced cell cycle arrest
To further investigate the function of Paip1 in GC cells,
we silenced Paip1 expression using siRNA in MGC803
and SGC-7901 cells. Western blot analysis showed that
Paip1 protein expression levels were significantly
decreased in MGC803 and SGC-7901 cells transfected
with specific siRNA compared with cells transfected with
control siRNA (Figure 3A). As shown in Figure 3B, silen-
cing Paip1 expression significantly inhibited the colony
formation ability of GC cells. Additionally, compared to
the negative control group, the number of EdU-positive
cells significantly decreased upon Paip1 siRNA transfec-
tion (Figure 3C), suggesting that silencing Paip1 expres-
sion decreased DNA synthesis. The speed of the cell cycle
is closely related to cell proliferation.13,14 We identified
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Figure 4 Silencing Paip1 inhibited cell cycle arrest.
Notes: (A) Flow cytometric analysis of the cell cycle indicated that Paip1 downregulation significantly induced MGC-803 and SGC-7901 cell cycle arrest in the G1/S phase.
(B) The cyclin D1 expression level in MGC-803 and SGC-7901 cells was decreased after siRNA1 silencing. Each bar represents the mean ± SD. *p<0.05, **p<0.01.
Abbreviations: siCON, non-targeting siRNA; siRNA, small interfering RNA.
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that silencing Paip1 induced cell cycle arrest in the G1/S
phases (Figure 4A). In addition, Western blot analysis
indicated that the expression of cyclin D1 was downregu-
lated after Paip1 silencing (Figure 4B). Therefore, our
studies demonstrated that silencing Paip1 expression
induced G1/S cell cycle arrest as the predominant mechan-
ism in the inhibition of cell proliferation.
Silencing Paip1 expression inhibited EMT
progression to prevent tumor metastasis
To identify the role of Paip1 in cell migration and inva-
sion, we performed a wound healing assay and Transwell
assays. The results showed that the cell migration and
invasion abilities were attenuated in Paip1-silenced cells
(Figure 5A–C). Epithelial-mesenchymal transition (EMT)
is the transition from polarized epithelial cancer cells to
contractile and motile mesenchymal cells during cancer
progression and metastasis.15 Paip1-silenced GC cells
were analyzed for key EMT markers, such as Snail,
vimentin and E-cadherin. The results showed that the
expression of the mesenchymal marker vimentin and the
EMT-related transcription factor snai1 were downregu-
lated in Paip1-silenced cells, while the expression of the
epithelial marker E-cadherin was significantly upregulated
(Figure 5D). Our experiments demonstrated that Paip1
regulated EMT progression to promote tumor metastasis.
Paip1 overexpression promoted
proliferation and metastasis in GC cell
To determine the biological functions of Paip1 in GC, we
established stable overexpression of Paip1 in MGC-803
and BGC823 cells. (Figure 6D). Colony formation assay
showed that Paip1 overexpression significantly promoted
the colony formation ability of GC cells. (Figure 6A). In
addition, Western blot analysis indicated that Paip1 over-
expression increased the expression of cyclin D1 in GC
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cells. (Figure 6D). To determine the role of Paip1 in cell
migration and invasion, we performed a wound healing
assay and Transwell assays. The results showed that Paip1
overexpression significantly promoted GC cell metastasis
(Figure 6B and C). Whether Paip1 was involved in the
regulation of EMT process of GC, we examined typical
EMT proteins. Western blotting indicated that after over-
expression in MGC-803 and BGC823 cells, the expression
of vimentin and snai1 levels reduced while E-cadherin
levels increased. (Figure 6D). These results indicated that
Paip1 overexpression promoted GC cell proliferation and
metastasis.
Discussion
Abnormal regulation at the initial stage of the translation
process leads to unusual gene expression that alters cell
growth and may lead to cancer development.16 Shull AY et
al reported the potential dependence of eukaryotic transla-
tion factor 4G (eIF4G) overexpression in chronic lympho-
cytic leukemia (CLL) survival.17 Simultaneously, Zhong
and associates showed that overexpression of eukaryotic
translation initiation factor 4A (eIF4A) conferred cancer
cells with resistance to cell death.18 A new human PABP-
interacting protein, Paip1, whose sequence is similar to the
central portion of eIF4G and interacts with eIF4A, results
in the stimulation of protein translation by binding PABP
and activating protein translation.19–21 Accordingly, we
hypothesized that Paip1 might be involved in the multi-
cellular function of cancer progression as a translation
initiation regulator.
Notably, for the first time, we demonstrated that Paip1
was significantly overexpressed at both the protein and
mRNA levels in GC tissues but rarely in adjacent normal
gastric tissues. These results demonstrated that Paip1 par-
ticipates in the process of GC progression. Additionally, in
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the univariate analysis, patient age, tumor invasion, lym-
phatic invasion, clinical stage and Paip1 were identified as
factors associated with the OS results (p<0.05). For the
multivariate analysis, tumor invasion and Paip1 were inde-
pendently associated with the OS results (p<0.05).
Similarly, Paip1 expression was more abundant in stage
II, III and IV GC than in stage I of GCs. Thus, Paip1
overexpression is correlated with late-stage cancers. Based
on our findings, we propose that Paip1 can be potentially
used as a novel therapeutic target for GC.
Although a high expression level of Paip1 was
observed in GC, the detailed molecular mechanisms by
which the overexpression of Paip1 promotes GC have not
been elucidated. In our previous study, we showed that
suppression of Paip1 expression inhibits breast cancer cell
proliferation.22 In this study, we found that the ability of
proliferation in GC cells were significantly inhibited with
the depletion of Paip1 and increased with the overexpres-
sion of Paip1 in vitro. Importantly, cell cycle analysis
showed that silencing Paip1 expression delayed G1/S
stage in GC cells. These results indicated that suppression
of Paip1 expression affected cell growth by inducing cell
cycle arrest. Patel et al reported that cyclinD1 overexpres-
sion may accelerate G1/S stage as a positive regulator of
cell cycle progression, accelerating cell proliferation.23 As
indicated by our data, Paip1 knockdown led to decreased
expression of Cyclin D1, whereas Paip1 overexpression
enhanced Cyclin D1 expression. These results supported
that Paip1 can control the progression of cell cycle by
regulating the expression level of Cyclin D1.
Metastasis involves a series of complex steps, includ-
ing reduced adhesion, increased motility, cell attachment,
matrix lysis and migration.24,25 We observed that the
increased levels of Paip1 is significantly correlated with
poor prognostic features such as lymphatic invasion
advanced tumor pathologic stage, and tumor TNM
stage. Previous studies have demonstrated that Paip1
might be involved in the invasion of cervical cancer.10
Furthermore, our results showed that after silencing
Paip1 expression, the migration distance and invasive-
ness of GC cells decreased, while Paip1 overexpression
exhibited the opposite results. These results reveal that
Paip1 prompted the migration and invasion in GC cells.
Based on the abovementioned results, we investigated the
underlying molecular mechanisms for promotion of
metastasis by Paip1 in greater detail. EMT is a key
process in tumor metastasis and is involved in the coor-
dinated regulation of many genes.26–28 In this study, we
discovered that Paip1 overexpression promoted EMT by
decreasing the expression of the mesenchymal markers
vimentin and snail and by elevating the expression of the
epithelial marker E-cadherin. These results confirmed
that Paip1 promoted cell migration and invasion by pro-
moting the process of EMT in GC. Further studies should
be conducted to determine the mechanism by which
Paip1 promotes GC metastasis by controlling the transla-
tion of EMT-related genes.
Conclusion
This study demonstrated that Paip1 overexpression is
strongly related to GC progression and is an independent
prognostic factor. Moreover, Paip1 overexpression pro-
moted cell proliferation, migration, invasion and EMT
progression in GC cells. Our findings indicated that
Paip1 may also represent a new molecular biomarker for
human GC.
Acknowledgments
This study was supported by the National Natural Science
Funds of China (No. 31760313, 31460303, 81660609), the
Funds of Changbai Mountain Scholar Project and Key
Laboratory of the Science and Technology Department of
Jilin Province.
Author contributions
Zhenhua Lin and Xianglan Zhang conceived this study and
takes responsibility for the quality of the data. Jie Sun and
Anna Han participated in the tissue sample selection
and experiments. Liyan Chen acquired data and played
an important role in interpreting the results. Qianrong
Wang performed the data analysis and wrote the manu-
script. Xiangshan Ren played an important role in modify-
ing the paper. All authors contributed to data analysis,
drafting or revising the article, gave final approval of the
version to be published, and agree to be accountable for all
aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J
Clin. 2018;68:7–30. doi:10.3322/caac.21442
2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric
cancer. Lancet. 2016;388:2654–2664. doi:10.1016/S0140-6736(16)
30354-3
Dovepress Wang et al
OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com
DovePress
6575
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
13
4.
20
7.
84
 o
n 
05
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015.
CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338
4. Craig AW, Haghighat A, Yu AT, Sonenberg N. Interaction of poly-
adenylate-binding protein with the eIF4G homologue PAIP enhances
translation. Nature. 1998;392:520–523. doi:10.1038/33198
5. Gray NK, Coller JM, Dickson KS, Wickens M. Multiple portions of
poly(A)-binding protein stimulate translation in vivo. Embo J.
2000;19:4723–4733. doi:10.1093/emboj/19.17.4723
6. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in
eukaryotes: mechanisms and biological targets. Cell. 2009;136:731–
745. doi:10.1016/j.cell.2009.01.042
7. Kong J, Lasko P. Translational control in cellular and developmental
processes. Nat Rev Genet. 2012;13:383–394. doi:10.1038/nrg3184
8. Spilka R, Ernst C, Mehta AK, Haybaeck J. Eukaryotic translation
initiation factors in cancer development and progression. Cancer Lett.
2013;340:9–21. doi:10.1016/j.canlet.2013.06.019
9. Sendoel A, Dunn JG, Rodriguez EH, et al. Translation from uncon-
ventional 5ʹ start sites drives tumour initiation. Nature.
2017;541:494–499. doi:10.1038/nature21036
10. Scotto L, Narayan G, Nandula SV, et al. Integrative genomics analy-
sis of chromosome 5p gain in cervical cancer reveals target over-
expressed genes, including Drosha. Mol Cancer. 2008;7:58.
doi:10.1186/1476-4598-7-58
11. Fukada Y, Yasui K, Kitayama M, et al. Gene expression analysis of
the murine model of amyotrophic lateral sclerosis: studies of the
Leu126delTT mutation in SOD1. Brain Res. 2007;1160:1–10.
doi:10.1016/j.brainres.2007.05.044
12. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a
portal for facilitating tumor subgroup gene expression and survival ana-
lyses. Neoplasia. 2017;19:649–658. doi:10.1016/j.neo.2017.05.002
13. Kushner JA, Ciemerych MA, Sicinska E, et al. Cyclins D2 and D1
are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol.
2005;25:3752–3762. doi:10.1128/MCB.25.9.3752-3762.2005
14. Sharma DK, Bressler K, Patel H, Balasingam N, Thakor N. Role of
eukaryotic initiation factors during cellular stress and cancer progres-
sion. J Nucleic Acids. 2016;2016:8235121. doi:10.1155/2016/8235121
15. Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell.
2016;166:21–45. doi:10.1016/j.cell.2016.06.028
16. Ruggero D. Translational control in cancer etiology. Cold Spring
Harb Perspect Biol. 2013;5(2):a012336. doi:10.1101/cshperspect
17. Shull AY, Noonepalle SK, Awan FT, et al. RPPA-based protein
profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phos-
phorylation as molecular events that correspond with a pro-survival
phenotype in chronic lymphocytic leukemia. Oncotarget.
2015;6:14632–14645. doi:10.18632/oncotarget.4104
18. Zhong X, Persaud L, Muharam H, et al. Eukaryotic translation
initiation factor 4A down-regulation mediates interleukin-24-induced
apoptosis through inhibition of translation. Cancers (Basel). 2018;10
(5). doi:10.3390/cancers10110400.
19. Zang Y, Zhang X, Yan L, et al. Eukaryotic translation initiation factor
3b is both a promising prognostic biomarker and a potential thera-
peutic target for patients with clear cell renal cell carcinoma. J
Cancer. 2017;8:3049–3061. doi:10.7150/jca.19594
20. Attar-Schneider O, Drucker L, Gottfried M. Migration and epithelial-
to-mesenchymal transition of lung cancer can be targeted via transla-
tion initiation factors eIF4E and eIF4GI. Lab Invest. 2016;96:1004–
1015. doi:10.1038/labinvest.2016.77
21. Imataka H, Gradi A, Sonenberg N. A newly identified N-terminal
amino acid sequence of human eIF4G binds poly(A)-binding protein
and functions in poly(A)-dependent translation. Embo J.
1998;17:7480–7489. doi:10.1093/emboj/17.24.7480
22. Piao J, Chen L, Jin T, Xu M, Quan C, Lin Z. Paip1 affects breast
cancer cell growth and represents a novel prognostic biomarker. Hum
Pathol. 2018;73:33–40. doi:10.1016/j.humpath.2017.10.037
23. Patel H, Abduljabbar R, Lai CF, et al. Expression of CDK7, Cyclin
H, and MAT1 Is elevated in breast cancer and is prognostic in
estrogen receptor-positive breast cancer. Clin Cancer Res.
2016;22:5929–5938. doi:10.1158/1078-0432.CCR-15-1104
24. Vleminckx K, Vakaet L Jr., Mareel M, Fiers W, van Roy F. Genetic
manipulation of E-cadherin expression by epithelial tumor cells
reveals an invasion suppressor role. Cell. 1991;66:107–119.
doi:10.1016/0092-8674(91)90143-m
25. Jewett A, Kos J, Fong Y, et al. NK cells shape pancreatic and oral
tumor microenvironments; role in inhibition of tumor growth and
metastasis. Semin Cancer Biol. 2018;53:178–188. doi:10.1016/j
26. Shook D, Keller R. Mechanisms, mechanics and function of epithe-
lial-mesenchymal transitions in early development. Mech Dev.
2003;120:1351–1383.
27. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive
oxygen species mediate MMP-3-induced EMT and genomic instabil-
ity. Nature. 2005;436:123–127. doi:10.1038/nature03688
28. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchy-
mal transitions in development and disease. Cell. 2009;139:871–890.
doi:10.1016/j.cell.2009.11.007
OncoTargets and Therapy Dovepress
Publish your work in this journal
OncoTargets and Therapy is an international, peer-reviewed, open
access journal focusing on the pathological basis of all cancers,
potential targets for therapy and treatment protocols employed to
improve the management of cancer patients. The journal also
focuses on the impact of management programs and new therapeutic
agents and protocols on patient perspectives such as quality of life,
adherence and satisfaction. The manuscript management system is
completely online and includes a very quick and fair peer-review
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal
Wang et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
OncoTargets and Therapy 2019:126576
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
13
4.
20
7.
84
 o
n 
05
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
